Insight

Jul 24, 2024, 11:18

Dendritic cell based-immunotherapy after adjuvant chemotherapy in resectable PDAC

Clémence Toullec, Head and Neck Medical Oncologist at Cancer Institute Avignon Provence – Sainte Catherine, shared a paper by Freek R. van ‘t Land et al, on LinkedIn:

“Outstanding efficacy of dendritic cell based-immunotherapy after adjuvant chemotherapy completion in resectable PDAC recently published in JCO.

Recurrence free survival rate at 2 years 68% in this phase I/II trial. Remember : 2 years RFS was only 42% in the FOLFIRINOX arm in the PRODIGE24 trial.

The way to go for future trials design.”

Source: Clémence Toullec/LinkedIn

Dendritic cell based-immunotherapy after adjuvant chemotherapy in resectable PDAC

Dendritic Cell–Based Immunotherapy in Patients With Resected Pancreatic Cancer

Authors: Freek R. van ‘t Land, Marcella Willemsen, Koen Bezemer, Sjoerd H. van der Burg, Thierry P.P. van den Bosch, Michail Doukas, Amine Fellah, P. Martijn Kolijn, Anton W. Langerak, Miranda Moskie, Elise van der Oost, Nina E.M. Rozendaal, Sara J. Baart, Joachim G.J.V. Aerts, and Casper H.J. van Eijck

cancer Cancer Institute Avignon Provence - Sainte Catherine Casper H.J. van Eijck dendritic cell based-immunotherapy FOLFIRINOX Freek R. van ‘t Land Joachim G.J.V. Aerts Koen Bezemer Marcella Willemsen Michail Doukas Miranda Moskie OncoDaily Oncology PRODIGE24

Aparna Parikh Has Been Named Program Director for the GI Medical Oncology Program at Mass General Brigham

Herbert Loong: Grateful for the Journey with ASCO International Affairs Committee

Unreleased Decision Letters From 2024–2025 Now Available - FDA

Servier and IDEAYA Biosciences Partner to Advance Darovasertib for Uveal Melanoma

FDA Grants Breakthrough Therapy Designation to Zongertinib (HERNEXEOS) for First-Line Treatment of HER2-Mutant Advanced NSCLC